Cardiology

This Heart Failure Awareness Week, revisit recent advancements and scope out the future of heart failure care with HCPLive.

Downey discusses the recent discovery of influenza’s interaction with the interferon 1 pathway, as well as a hypothetical method for preventing it.

Rizik and Morris discuss the Heartflow PCI Navigator, which analyzes CT scans to generate 3D models of calcium blockages ahead of procedures.

Desai discusses his recent observational cohort study indicating finerenone’s substantial reduction of heart failure exacerbation risk in patients with HFpEF.

Wu discusses his recent study spotlighting food source and quality as a more significant influence on CHD risk compared to simply cutting carbs or fat.

Bress highlights the potential shortcomings of relying on the Apple Watch as a diagnostic tool for hypertension, discussing its potential for false negatives.

Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.

Hardy discussed the disparity between treatment access and usage, highlighting the fact that most patients are within 10 mmHg of guideline recommendations.

Ruff explains his prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, highlighting abelacimab’s efficacy and durability compared to rivaroxaban.

Russman highlights asundexian’s efficacy in patients following a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

Sorajja describes his team’s operation to implant the ring via a novel trans-septal system, effectively avoiding the need to stop the heart in MR treatment.

Greene discusses his recent study highlighting the limitations of quadruple therapy in reducing mortality and hospitalization rates among patients with HFrEF.

Catch up with major FDA decisions, key guidelines updates, and more.

Freedman discusses a new analysis of the CARDIA study that indicates male patients’ greater risk of CHD at younger ages.

Kianersi discusses how, although evening chronotype can be associated indirectly with increased CVD risk, this can be mediated via Life’s Essential 8 scores.

Milestone Pharmaceuticals’ novel, self-administered medication for paroxysmal supraventricular tachycardia has released alongside a patient support program.

The new approval allows for repeat administration of iDose TR, modifying the existing single-administration label.

Frikke-Schmidt discusses the newfound genetic correlation between vascular-related dementia and an increased BMI, partially mediated by high blood pressure.

Abou-Ghayda breaks down the association between ED and CVD and how this study introduces a new way to address this sensitive topic.

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 data and updated asthma guidelines, in this week’s essential news roundup.

MacDougall discusses the Family Heart Foundation’s recent study indicating that very few adults with ASCVD are receiving guideline-directed therapy.

Palaniappan explains what steps to take in managing cardiovascular disease risk among a population that does not adhere to the Life’s Essential 8 guidelines.

Despite being considered superior to in-clinic measurements, a substantial number of patients do not follow the HBPM guideline recommendations of 12 readings per week.

Recent research shows a substantial portion of US youths have increased risk of cardiometabolic diseases due to obesity and overweight.